Af­ter two rounds of mixed da­ta, Eli Lil­ly im­press­es an­a­lysts with new Covid-19 an­ti­body re­sults. And ex­ecs want an EUA now

Eli Lil­ly has more da­ta from their Covid-19 neu­tral­iz­ing an­ti­bod­ies — da­ta, they say, should war­rant an FDA OK.

The Big Phar­ma said Wednes­day that a cock­tail of two mon­o­clon­al an­ti­bod­ies looked safe and re­duced vi­ral load in Covid-19 pa­tients. It al­so al­le­vi­at­ed symp­toms and re­duced ER vis­its and hos­pi­tal­iza­tion rate com­pared to place­bo, ap­pear­ing over­all to pro­vide bet­ter re­sults than a sin­gle Lil­ly an­ti­body showed in Sep­tem­ber and to com­pare fa­vor­ably with the Re­gen­eron an­ti­body cock­tail that Pres­i­dent Trump re­ceived last week.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.